The impact of risk factors on aspirin's efficacy for the prevention of preterm birth.


Journal

American journal of obstetrics & gynecology MFM
ISSN: 2589-9333
Titre abrégé: Am J Obstet Gynecol MFM
Pays: United States
ID NLM: 101746609

Informations de publication

Date de publication:
10 2023
Historique:
received: 11 04 2023
revised: 05 07 2023
accepted: 13 07 2023
medline: 27 11 2023
pubmed: 14 8 2023
entrez: 13 8 2023
Statut: ppublish

Résumé

The Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas trial was a landmark study that demonstrated a reduction in preterm birth and hypertensive disorders of pregnancy in nulliparous women who received low-dose aspirin. All women in the study had at least 1 moderate-risk factor for preeclampsia (nulliparity). Unlike current US Preventative Service Task Force guidelines, which recommend low-dose aspirin for ≥2 moderate-risk factors, women in this study were randomized to receive low-dose aspirin regardless of the presence or absence of an additional risk factor. This study aimed to compare how low-dose aspirin differentially benefits nulliparous women with and without additional preeclampsia risk factors for the prevention of preterm birth and hypertensive disorders of pregnancy. This was a non-prespecified secondary analysis of the Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas trial that randomized nulliparous women with singleton pregnancies from 6 low-middle-income countries to receive low-dose aspirin or placebo. Our primary exposure was having an additional preeclampsia risk factor beyond nulliparity. Our primary outcome was preterm birth before 37 weeks of gestation, and our secondary outcomes included preterm birth before 34 weeks of gestation, preterm birth before 28 weeks of gestation, hypertensive disorders of pregnancy, and perinatal mortality. Among 11,558 nulliparous women who met the inclusion criteria, 66.8% had no additional risk factors. Low-dose aspirin similarly reduced the risk of preterm birth at <37 weeks of gestation in women with and without additional risk factors (relative risk: 0.75 vs 0.85; P=.35). Additionally for our secondary outcomes, low-dose aspirin similarly reduced the risk of preterm birth at <28 weeks of gestation, hypertensive disorders of pregnancy, and perinatal mortality in women with and without additional risk factors. The reduction of preterm birth at <34 weeks of gestation with low-dose aspirin was significantly greater in women without additional risk factors than those with an additional risk factor (relative risk: 0.69 vs 1.04; P=.04). Low-dose aspirin's ability to prevent preterm birth, hypertensive disorders of pregnancy, and perinatal mortality was similar in nulliparous women with and without additional risk factors. Professional societies should consider recommending low-dose aspirin to all nulliparous women.

Sections du résumé

BACKGROUND
The Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas trial was a landmark study that demonstrated a reduction in preterm birth and hypertensive disorders of pregnancy in nulliparous women who received low-dose aspirin. All women in the study had at least 1 moderate-risk factor for preeclampsia (nulliparity). Unlike current US Preventative Service Task Force guidelines, which recommend low-dose aspirin for ≥2 moderate-risk factors, women in this study were randomized to receive low-dose aspirin regardless of the presence or absence of an additional risk factor.
OBJECTIVE
This study aimed to compare how low-dose aspirin differentially benefits nulliparous women with and without additional preeclampsia risk factors for the prevention of preterm birth and hypertensive disorders of pregnancy.
STUDY DESIGN
This was a non-prespecified secondary analysis of the Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas trial that randomized nulliparous women with singleton pregnancies from 6 low-middle-income countries to receive low-dose aspirin or placebo. Our primary exposure was having an additional preeclampsia risk factor beyond nulliparity. Our primary outcome was preterm birth before 37 weeks of gestation, and our secondary outcomes included preterm birth before 34 weeks of gestation, preterm birth before 28 weeks of gestation, hypertensive disorders of pregnancy, and perinatal mortality.
RESULTS
Among 11,558 nulliparous women who met the inclusion criteria, 66.8% had no additional risk factors. Low-dose aspirin similarly reduced the risk of preterm birth at <37 weeks of gestation in women with and without additional risk factors (relative risk: 0.75 vs 0.85; P=.35). Additionally for our secondary outcomes, low-dose aspirin similarly reduced the risk of preterm birth at <28 weeks of gestation, hypertensive disorders of pregnancy, and perinatal mortality in women with and without additional risk factors. The reduction of preterm birth at <34 weeks of gestation with low-dose aspirin was significantly greater in women without additional risk factors than those with an additional risk factor (relative risk: 0.69 vs 1.04; P=.04).
CONCLUSION
Low-dose aspirin's ability to prevent preterm birth, hypertensive disorders of pregnancy, and perinatal mortality was similar in nulliparous women with and without additional risk factors. Professional societies should consider recommending low-dose aspirin to all nulliparous women.

Identifiants

pubmed: 37574046
pii: S2589-9333(23)00237-9
doi: 10.1016/j.ajogmf.2023.101095
pii:
doi:

Substances chimiques

Aspirin R16CO5Y76E

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101095

Subventions

Organisme : NICHD NIH HHS
ID : UG1 HD076465
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD078439
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Emily E Nuss (EE)

Christiana Care, Newark, DE (Drs Nuss and Hoffman). Electronic address: emilynuss1@gmail.com.

Matthew K Hoffman (MK)

Christiana Care, Newark, DE (Drs Nuss and Hoffman).

Shivaprasad S Goudar (SS)

Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belgaum, India (Drs Goudar, Kavi, Metgud, and Somannavar).

Avinash Kavi (A)

Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belgaum, India (Drs Goudar, Kavi, Metgud, and Somannavar).

Mrityunjay Metgud (M)

Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belgaum, India (Drs Goudar, Kavi, Metgud, and Somannavar).

Manjunath Somannavar (M)

Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belgaum, India (Drs Goudar, Kavi, Metgud, and Somannavar).

Jean Okitawutshu (J)

Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo (Drs Okitawutshu, Lokangaka, and Tshefu).

Adrien Lokangaka (A)

Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo (Drs Okitawutshu, Lokangaka, and Tshefu).

Antoinette Tshefu (A)

Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo (Drs Okitawutshu, Lokangaka, and Tshefu).

Melissa Bauserman (M)

University of North Carolina at Chapel Hill, Chapel Hill, NC (Dr Bauserman).

Abigail Mwapule Tembo (AM)

University Teaching Hospital, Lusaka, Zambia (Ms Tembo and Dr Chomba).

Elwyn Chomba (E)

University Teaching Hospital, Lusaka, Zambia (Ms Tembo and Dr Chomba).

Waldemar A Carlo (WA)

University of Alabama at Birmingham, Birmingham, AL (Dr Carlo).

Lester Figueroa (L)

Instituto de Nutrición de Centro América y Panamá, Guatemala City, Guatemala (Dr Figueroa).

Nancy F Krebs (NF)

University of Colorado Denver, Denver, CO (Dr Krebs).

Saleem Jessani (S)

Aga Khan University, Karachi, Pakistan (Drs Jessani and Saleem).

Sarah Saleem (S)

Aga Khan University, Karachi, Pakistan (Drs Jessani and Saleem).

Robert L Goldenberg (RL)

Columbia University, New York, NY (Dr Goldenberg).

Kunal Kurhe (K)

Lata Medical Research Foundation, Nagpur, India (Drs Kurhe and Das).

Prabir Das (P)

Lata Medical Research Foundation, Nagpur, India (Drs Kurhe and Das).

Patricia L Hibberd (PL)

Boston University School of Public Health, Boston, MA (Dr Hibberd).

Emmah Achieng (E)

Department of Child Health and Paediatrics, Moi University School of Medicine, Eldoret, Kenya (Ms Achieng and Drs Nyongesa and Esamai).

Paul Nyongesa (P)

Department of Child Health and Paediatrics, Moi University School of Medicine, Eldoret, Kenya (Ms Achieng and Drs Nyongesa and Esamai).

Fabian Esamai (F)

Department of Child Health and Paediatrics, Moi University School of Medicine, Eldoret, Kenya (Ms Achieng and Drs Nyongesa and Esamai).

Edward A Liechty (EA)

School of Medicine, Indiana University, Indianapolis, IN (Drs Liechty and Bucher).

Sherri Bucher (S)

School of Medicine, Indiana University, Indianapolis, IN (Drs Liechty and Bucher).

Norman Goco (N)

RTI International, Research Triangle Park, NC (Mr Goco, Mses Hemingway-Foday and Moore, and Dr McClure).

Jennifer Hemingway-Foday (J)

RTI International, Research Triangle Park, NC (Mr Goco, Mses Hemingway-Foday and Moore, and Dr McClure).

Janet Moore (J)

RTI International, Research Triangle Park, NC (Mr Goco, Mses Hemingway-Foday and Moore, and Dr McClure).

Elizabeth M McClure (EM)

RTI International, Research Triangle Park, NC (Mr Goco, Mses Hemingway-Foday and Moore, and Dr McClure).

Robert M Silver (RM)

University of Utah, Salt Lake City, UT (Dr Silver).

Richard J Derman (RJ)

Thomas Jefferson University, Philadelphia, PA (Dr Derman).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH